08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

Advicor extended release lovastatin/niacin data

In a retrospective, post-marketing analysis of 6,574 adults taking corticosteroids for asthma, patients who also received statin treatment for a cardiovascular condition had a lower rate of hospitalization or ER visit for asthma over 12...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Company News

Kos, Abbott deal

ABT announced plans to acquire KOSP for $78 per share, or about $3.7 billion in cash. The takeout price is a 56% premium to KOSP's close of $50.09 on Nov. 3, the last trading day...
08:00 , Nov 13, 2006 |  BioCentury  |  Finance

Ebb & Flow

In August 2005, when...
03:04 , Nov 7, 2006 |  BC Extra  |  Company News

Abbott to acquire Kos

KOSP gained $26.97 (54%) to $77.06 on Monday after ABT announced plans to acquire the cardiovascular, metabolic and pulmonary company for $78 per share, or about $3.7 billion in cash. The takeout price represents a...
08:00 , Nov 14, 2005 |  BioCentury  |  Strategy

Winning through sharing

In Kos Pharmaceuticals Inc. , Jerini AG found a partner willing to share marketing rights while helping to finance development, something it said other potential partners were unwilling to do. Thus, Jerini last week granted...
07:00 , Apr 18, 2005 |  BC Week In Review  |  Company News

Kos, Barr Laboratories Inc. sales and marketing update

KOSP and BRL's Duramed Pharmaceuticals subsidiary will co-promote KOSP's Niaspan extended-release niacin and Advicor extended-release niacin/lovastatin cholesterol drugs. Duramed will be eligible for royalties. Also, the companies settled litigation in the U.S. District Court for...
07:00 , Aug 9, 2004 |  BioCentury  |  Finance

Ebb & Flow

Six substantial venture rounds - three each in the U.S. and Europe - brought in $166.1 million last week, but the differences between the rounds illustrates the continued lag in European funding. Thus, three U.S....
08:00 , Dec 15, 2003 |  BC Week In Review  |  Clinical News

Advicor extended release niacin combined with immediate- release lovastatin regulatory update

KOSP said marketing partner Oryx Pharmaceuticals Inc. (Mississauga, Ontario) submitted NDSs for Canadian approval of Advicor and Niaspan both to treat lipid disorders. The companies expect Canadian approval in the second half of 2005. The...
08:00 , Dec 12, 2003 |  BC Extra  |  Company News

KOSP partner submits Niaspan, Advicor NDSs

Kos (KOSP) said marketing partner Oryx (Mississauga, Ontario) submitted NDSs for Canadian approval of Niaspan extended release niacin and Advicor extended release niacin/lovastatin, both to treat lipid disorders. The companies expect Canadian approval in the...